Brief: ChemoCentryx Announces EU Approval Of Tavneos (Avacopan) For The Treatment Of Anca-Associated Vasculitis

Churchill Capital XI

19/01/2022 13:50

Jan 19 (Reuters) - ChemoCentryx Inc  CCXI.O :
    * CHEMOCENTRYX ANNOUNCES EU APPROVAL OF TAVNEOS® (AVACOPAN)
FOR
THE TREATMENT OF ANCA-ASSOCIATED VASCULITIS
    * CHEMOCENTRYX INC -  TAVNEOS LAUNCH EXPECTED IN H1 2022
WITHIN
EUROPEAN UNION

Source text for Eikon:  ID:nGNX7bDCVn 
Further company coverage:  CCXI.O 

 ((reuters.briefs@thomsonreuters.com;))